Free Trial
OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Price, News & Analysis

Arch Therapeutics logo

About Arch Therapeutics Stock (OTCMKTS:ARTH)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.00
$0.24
52-Week Range
N/A
Volume
N/A
Average Volume
4,068 shs
Market Capitalization
$6 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Stock News Headlines

Trump Makes Major Crypto Announcement
Pay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift all boats equally. They're wrong. One project stands to benefit more than any other – not by accident, but seemingly by design.
Arch Therapeutics, Inc. (ARTH)
Arch Therapeutics Inc ARTH
See More Headlines

ARTH Stock Analysis - Frequently Asked Questions

Arch Therapeutics, Inc. (OTCMKTS:ARTH) released its earnings results on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01.

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Arista Networks (ANET), Adobe (ADBE), GE Aerospace (GE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
7/23/2020
Today
7/03/2025
Next Earnings (Estimated)
8/18/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.98 million
Net Margins
-8,257.70%
Pretax Margin
-8,257.70%

Debt

Sales & Book Value

Annual Sales
$80 thousand
Price / Cash Flow
N/A
Book Value
($2.43) per share
Price / Book
N/A

Miscellaneous

Free Float
4,529,000
Market Cap
$6 thousand
Optionable
Not Optionable
Beta
4.02

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:ARTH) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners